A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab T
Merck MK3475-587
Description
This study will collect information on patients receiving pembrolizumab alone or in combination with lenvatinib or other cancer treatments. Information about your cancer treatment and lab or imaging test results ordered by your doctor. Participants will be followed for 10 yrs.
Protocol#: MK3475-587
Study Information
Age Group: Adults
Participating Sites: Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: III
Participating Sites: Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: III
Principal Investigator(s)
Amit Panwalkar
, MD
Steven Powell
Department
Management Group:
Solid Tumors
NCT:
NCT03486873
Contact Us
For more information on clinical trials at Sanford Health, call one of our regional clinical research offices:
Sanford Fargo Region: (701) 234-2383
Sanford Sioux Falls Region: (605) 328-1368